Rosetta Genomics and Sheba Medical Centre have entered a research agreement to develop and evaluate the efficacy of microRNA biomarkers to analyse the response of the drug nivolumab in lung cancer patients.

According to the agreement, Sheba Medical Centre will be responsible for collection of whole blood, peripheral blood mononuclear cells (PBMCs) and serum samples, while Rosetta Genomics will be responsible to identify the miRNAs associated with the response by using its proprietary microarray design and qRT-PCR platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Enamine and Pcovery have entered an agreement to develop novel drugs for the treatment of invasive fungal infections.

"The agreement enables the partners to develop a new technology platform for the treatment of fungal infections."

The two partners will jointly develop new composition of matter generation, and the IP produced will belong to Pcovery.

The agreement enables the partners to develop a new technology platform for the treatment of fungal infections.

Wuxi Biologics has signed a memorandum of understanding (MOU) with Prima Biomed Ltd to form a strategic biologics development and manufacturing partnership for the development of IMP321.

According to the agreement, Prima Biomed will be responsible for clinical manufacture of IMP321 in China, Macau, Taiwan and Hong Kong, while Wuxi Biologics will be responsible for the other parts of the world.

The partnership enables the two partners to develop a novel immunotherapy candidate for the treatment of cancer.

Pharming Group plans to raise gross proceeds of approximately $47.7m through the private placement of bonds.

Roth Capital Partners and Stifel Nicolaus Europe are acting as the placements agents for the offering.

The company plans to invest the funds to acquire all commercialisation rights to Ruconest in North America from Valeant Pharma and also increase the sales of Ruconest.

Fate Therapeutics plans to raise $37.5m through the private placement of 2.8 million shares of class A convertible preferred stock.

The company plans to use the proceeds to further develop its product pipeline for cellular immunotherapies and general corporate purposes.